Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas

Abstract

Brentuximab vedotin (BV) has demonstrated efficacy against CD30⁺ peripheral T-cell lymphoma (PTCL). We herein report a case of CD30⁺ peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) that emerged one month after completing BV, cyclophosphamide, doxorubicin, and prednisone (BV-CHP) therapy for anaplastic large cell lymphoma (ALCL) and responded to retreatment with BV monotherapy. This case suggests that CD30⁺ PTCL emerging shortly after BV-CHP therapy may respond to retreatment with BV monotherapy, even if the phenotype differs from the initial diagnosis.